Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.52 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040918 | 1.00 | EPHX2 (0.52) | EPHX2CTRB1NPC1RAB9ASIGMAR1 | |
| SCHEMBL3047174 | 0.88 | EPHX2 (0.60) | EPHX2NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3054999 | 0.88 | EPHX2 (0.60) | EPHX2NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL3706360 | 0.82 | DPP4 (0.47) | CTRB1SIGMAR1SMN1; SMN2PIN1CTSL | |
| SCHEMBL8820357 | 0.80 | MAPK1 (0.51) | CTRB1NPC1RAB9ASIGMAR1SMN1; SMN2 | |
| SCHEMBL3059934 | 0.76 | DPP4 (0.47) | CTRB1SIGMAR1SMN1; SMN2PIN1CTSL | |
| SCHEMBL3058398 | 0.76 | DPP4 (0.47) | CTRB1SIGMAR1SMN1; SMN2PIN1CTSL | |
| SCHEMBL3045267 | 0.76 | DPP4 (0.47) | CTRB1SIGMAR1SMN1; SMN2PIN1CTSL | |
| SCHEMBL7468481 | 0.72 | SIGMAR1 (0.51) | SIGMAR1SMN1; SMN2HPGD | |
| SCHEMBL17944509 | 0.72 | SIGMAR1 (0.51) | SIGMAR1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | EPHX2 1742/4885CTRB1 3963/4885NPC1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.